Edgar Filing: BRAINSTORM CELL THERAPEUTICS INC. - Form 4

BRAINSTO Form 4 August 31,	ORM CELL THE	RAPEUTI	CS INC						
FORM 4 Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction FORM 4			S SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 F CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES Section 16(a) of the Securities Exchange Act of 1934, Public Utility Holding Company Act of 1935 or Section of the Investment Company Act of 1940					N OMB Number: Expires: Estimated burden hou response.	urs per
1(b). (Print or Type	Responses)								
1. Name and Pinkas Alc		2. Issuer Name and Ticker or Trading Symbol BRAINSTORM CELL THERAPEUTICS INC. [BCLI]				5. Relationship of Reporting Person(s) to Issuer (Check all applicable)			
(Last) C/O BRAI THERAPE UNIVERS SUITE 320		3. Date of Earliest Transaction (Month/Day/Year) 08/27/2015				X_ Director 10% Owner Officer (give title Other (specify below) below)			
	(Street)			endment, D onth/Day/Yea	-	ıl	6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting Person Form filed by More than One Reporting		
HACKEN	SACK, NJ 07601						Person	More than One R	eporting
(City)	(State)	(Zip)	Tab	le I - Non-l	Derivative	Securities A	cquired, Disposed	of, or Beneficia	lly Owned
1.Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)		Date, if	3. Transactio Code (Instr. 8)	Disposed (Instr. 3, 4	(A) or of (D) 4 and 5) (A) or	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Reminder: Re	eport on a separate lin	e for each cla	ss of sec		Perso inform requir	ns who res nation cont red to respo lys a curre		n are not rm	SEC 1474 (9-02)

 Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned

 (e.g., puts, calls, warrants, options, convertible securities)

1. Title of 2. 3. Transaction Date 3A. Deemed 5. Number of 6. Date Exercisable and 7. Title and Amount of 4. Derivative Conversion (Month/Day/Year) Execution Date, if TransactionDerivative **Expiration Date** Underlying Securities Security or Exercise any Code Securities (Month/Day/Year) (Instr. 3 and 4) Price of (Month/Day/Year) (Instr. 8) (Instr. 3) Acquired (A) Derivative or Disposed of Security (D) (Instr. 3, 4, and 5) Amount Expiration or Date Exercisable Title Date Number Code V (A) (D) of Share Stock Option Common \$ 0.75 08/27/2015 15,333 09/27/2015(1) 08/27/2025 15,33 Α Stock (right to buy) **Reporting Owners** Relationships **Reporting Owner Name / Address** 10% Owner Officer Other Director Pinkas Alon C/O BRAINSTORM CELL THERAPEUTICS INC. Х 3 UNIVERSITY PLAZA DRIVE, SUITE 320 HACKENSACK, NJ 07601 **Signatures**

/s/ Thomas B. Rosedale (Pursuant to Power of Attorney)

**Signature of Reporting Person

Explanation of Responses:

* If the form is filed by more than one reporting person, see Instruction 4(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Option vests and becomes exercisable in 12 consecutive, equal monthly installments commencing on September 27, 2015 until fully (1) vested and exercisable on August 27, 2016, provided that the reporting person remains a director of Brainstorm Cell Therapeutics on each

vesting date.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

Edgar Filing: BRAINSTORM CELL THERAPEUTICS INC. - Form 4

08/31/2015

Date